COPD is a long-term lung disease that makes it hard to breathe. It results from a combination of chronic bronchitis and emphysema resulting in damage to the airways and the lung tissues. There are several treatment options available for COPD including bronchodilators, corticosteriods, vaccinations, oxygen therapy and lung transplants.
The aim of Chronic Obstructive Pulmonary Disease (COPD) Diagnosis Market is to alleviate symptoms, slow progression of disease, prevent and treat complications and enhance quality of life.
The chronic obstructive pulmonary disease (COPD) diagnosis market is estimated to be valued at USD 2.18 billion in 2024 and is expected to reach USD 3.05 billion by 2031, growing at a compound annual growth rate (CAGR) of 4.9% from 2024 to 2031.
Key Takeaways
Key players operating in the COPD therapeutics market are GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc, Pfizer Inc., and AstraZeneca.
COPD poses a major economic burden globally in terms of direct healthcare costs as well as indirect costs related to morbidity and mortality. With growing prevalence of COPD across both developed and developing nations, the market offers significant opportunities for manufacturers in developing countries with large patient population and unmet needs. Major players are focusing on expanding their geographical presence in emerging markets through collaborations with regional/local players. Emerging Asian countries such as India and China represent major markets with substantial future growth potential driven by growing awareness, large base of smoker population and improving access to healthcare facilities and diagnostics.
Market drivers: Rising prevalence of COPD worldwide, along with increasing healthcare expenditure particularly in emerging nations, are key factors anticipated to drive the global COPD therapeutics market growth over the forecast period. According to WHO, COPD is projected to become the 3rd leading cause of death globally by 2030. Growing environmental pollution levels along with rising cigarette smoking rates particularly in developing nations are other important drivers fuelling the market demand.
Market restraints: High cost of branded drugs along with limited affordability of patients in low-income nations act as a major restraint. Poor access to diagnosis in resource-poor rural areas also limits market growth. Moreover, presence of alternative treatment modes including generic drugs poses tough competition to established brands. Patent expiries of blockbuster drugs result in decline of revenues of major players. Stringent regulatory processes further delay product launch and market entry.
Segment Analysis Chronic Obstructive Pulmonary Disease (COPD) is an umbrella term for chronic inflammatory lung diseases. The major segment in COPD market is chronic bronchitis which causes long term damage, thickening and scarring of bronchial airways. Chronic bronchitis is dominating sub segment as approximately 9 out of 10 COPD patients suffer from chronic bronchitis leading to obstruction of airflow from the lungs. Long term inflammation from chronic bronchitis makes it the major cause of COPD.
Global Analysis North America region dominates the global COPD market due to high prevalence of smoking population suffering from COPD. As per estimates, there are around 15 million COPD sufferers in USA alone. Availability of advanced diagnostic centers and adoption of new drug therapies have propelled the market growth in North America. Asia Pacific region is witnessing fastest growth in COPD market owing to rising pollution levels, growing elderly population and changing lifestyle related risk factors in developing countries like India and China. Increasing healthcare spending and awareness about early diagnosis is fueling the regional market growth.
Get this Report in Japanese Language: 慢性閉塞性肺疾患（COPD）診断市場
Get this Report in Korean Language: 만성 폐쇄성 폐질환(COPD) 진단 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
